A 1-Year Safety Study of Dulaglutide in Japanese Patients With Type 2 Diabetes on a Single Oral Hypoglycemic Agent: An Open-Label, Nonrandomized, Phase 3 Trial
Endocrine Journal - Japan
doi 10.1507/endocrj.ej15-0401
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2015
Authors
Publisher
Japan Endocrine Society